Lykos Therapeutics (formerly MAPS PBC)
Wael Garas is a hospitalist with extensive experience in various medical roles. Currently serving as a hospitalist since April 2023, Wael has also worked as a researcher at MAPS Public Benefit Corporation since 2019, contributing as a co-principal investigator and study physician for Phase 2 and 3 trials involving MDMA for PTSD. Previous roles include primary care physician and hospitalist at Boulder Community Health from 2015 to October 2022, medical director of integrative medicine at SCL Health from 2011 to 2014, and hospitalist at Sound Physicians from 2007 to 2011. Wael's educational background includes an integrative medicine fellowship at the University of Arizona College of Medicine, an internal medicine residency at the University of Nevada School of Medicine, and a Doctor of Medicine degree from The Ohio State University College of Medicine.
Lykos Therapeutics (formerly MAPS PBC)
At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com.